To address this challenge, studies with combination therapies are ongoing, such as CHRYSALIS-2, assessing amivantamab and lazertinib versus lazertinib monotherapy in patients with EGFR-mutant NSCLC, and will include patients with treated brain metastases [106]. Here, EGFR is linked to non-small cell lung carcinoma.